stiripentol   

GtoPdb Ligand ID: 5469

Synonyms: BCX 2600 | Diacomit ®
stiripentol is an approved drug (EMA (2007), FDA (2018))
Compound class: Synthetic organic
Comment: Stiripentol is an orally active anti-epilepsy drug. Chemically is a mixture of enantiomers. The structure shown here does not specify stereochemistry at the chiral centres and is used to represent the mixture. Click here to view the PubChem records for associated stereoisomers.
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 1
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 38.69
Molecular weight 234.13
XLogP 2.88
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Canonical SMILES OC(C(C)(C)C)C=Cc1ccc2c(c1)OCO2
Isomeric SMILES OC(C(C)(C)C)/C=C/c1ccc2c(c1)OCO2
InChI InChI=1S/C14H18O3/c1-14(2,3)13(15)7-5-10-4-6-11-12(8-10)17-9-16-11/h4-8,13,15H,9H2,1-3H3/b7-5+
InChI Key IBLNKMRFIPWSOY-FNORWQNLSA-N
No information available.
Summary of Clinical Use
May be used as an adjunct in the treatment of epilepsy. In particular, this drug is indicated for the treatment of severe myoclonic epilepsy in infancy (SMEI or Dravet's syndrome). FDA approval as a treatment for the siezures associated with Dravet's syndrome was granted in August 2018, with approval including children 2 years of age and older whose symptoms are inadequately controlled by clobazam.
Mechanism Of Action and Pharmacodynamic Effects
Stiripentol appears to increase inhibitory GABA transmission, by increasing the duration of opening of GABAA channels. It may also improve the effectiveness of other anticonvulsants.
External links